Transcode Therapeutics, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Transcode Therapeutics amended its Series C Non-Voting Convertible Preferred Stock certificate on July 15, 2026, increasing the Beneficial Ownership Limitation from 4.99% to 9.99% of outstanding common shares per holder. The company has 1,214,204 shares of Series C preferred outstanding (par value $0.0001 each). This permits holders to convert to common stock up to the higher 9.99% threshold, subject to stockholder approval. The amendment was approved by majority vote of Series C preferred holders.
Why this rating
Routine preferred stock amendment; administrative increase to conversion cap. No capital raised, no immediate dilution. Relative to $6.5M market cap, structure change is modest operational governance matter.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.